Seres Therapeutics (MCRB) Misses Q2 EPS by 24c

August 11, 2016 7:02 AM EDT
Get Alerts MCRB Hot Sheet
Trade MCRB Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Seres Therapeutics (NASDAQ: MCRB) reported Q2 EPS of ($0.70), $0.24 worse than the analyst estimate of ($0.46). Revenue for the quarter came in at $3 million versus the consensus estimate of $4.2 million.

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities


Add Your Comment